Fulgent GeneticsFLGT +2.86%59 Days Payable is 36.56 as of Mar. 2026, which is 6% below its 10-year median of 38.88. GuruFocus rates FLGT with a GF Score™ of 59/100 and a GF Value™ of $23.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 75.79% on this metric.
The historical rank and industry rank for Fulgent Genetics's Days Payable or its related term are showing as below:
FLGT'
s Days Payable Range Over the Past 10 Years
Min: 31.56 Med: 38.88 Max: 103.4
Current: 35.32
During the past 12 years, Fulgent Genetics's highest Days Payable was 103.40. The lowest was 31.56. And the median was 38.88.
FLGT's Days Payable is ranked worse than 75.79% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs FLGT: 35.32
Fulgent Genetics's Days Payable
declined
from Mar. 2025 (37.01) to Mar. 2026 (36.56).
It may suggest that Fulgent Geneticsaccelerated paying its suppliers.
Fulgent Genetics Days Payable Related Terms
Fulgent Genetics Days Payable Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Fulgent Genetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Days Payable distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fulgent Genetics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (FLGT) has a Days Payable of 36.56 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fulgent Genetics and its competitors. This is near median its historical median of 38.88. Over the past decade, Fulgent Genetics' Days Payable has ranged from 31.56 to 103.40. According to the industry distribution chart, Fulgent Genetics ranks #144 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 75.8%.
Is Fulgent Genetics' Days Payable too high?
Fulgent Genetics' current Days Payable of 36.56 is near median its 10-year median of 38.88. Over the past 10 years, this metric has ranged from a low of 31.56 to a high of 103.40. The Medical Diagnostics & Research industry median Days Payable is 67.28. Fulgent Genetics' value of 36.56 is 45.7% below this industry median. Based on the distribution chart, Fulgent Genetics ranks #144 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fulgent Genetics has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Days Payable compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #144 out of 190 companies for Days Payable. This places Fulgent Genetics in the lower half of its industry. The industry median Days Payable is 67.28. Fulgent Genetics' value of 36.56 is 45.7% below this benchmark. Historically, Fulgent Genetics' own Days Payable has ranged from 31.56 to 103.40 over the past decade. While the company's 10-year median is 38.88 vs. the industry median of 67.28, Fulgent Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulgent Genetics's current Days Payable of 36.56 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Days Payable is 36.56, which is near median its own 10-year median of 38.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.99, compared to a current price of $20.53 — trading 14.4% below its estimated fair value. The current Days Payable is 36.56, which is near median its 10-year median of 38.88 and 45.7% below the Medical Diagnostics & Research industry median of 67.28. Fulgent Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Days Payable is 36.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $20.53 is trading 14.4% below its estimated GF Value™ of $23.99.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Days Payable: 36.56 (near median its 10-year median of 38.88)
GF Value™: $23.99 vs. price of $20.53 (14.4% below fair value)
Industry Position: 45.7% below the Medical Diagnostics & Research median (#144 of 190)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
59GF Score
Get the complete analysis for FLGT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
